NCT06644404

Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults

A Randomized, Open, Two-sequence, Crossover, Multiple Oral Administrations, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Drug-drug Interaction Between DWP16001, DWC202407, and DWC202408 in Healthy Adults

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This study aims to evaluate the pharmacokinetic/pharmacodynamic drug-drug interactions between DWP16001, DWC202407, and DWC202408 in healthy adults

Detailed description

This study aims to evaluate the pharmacokinetic interactions, pharmacodynamic interactions, safety, and tolerability of DWP16001, DWC202407, and DWC202408 in healthy adults

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	DWP16001 0.3mg	1 tablet, Orally, Once daily single dose
DRUG	DWC202407 1,000mg	1 tablet, Orally, Twice daily
DRUG	DWC202408 2mg	1 tablet, Orally, Once daily single dose

Timeline

• Start date: 2024-10-26
• Primary completion: 2024-12-03
• Completion: 2025-04-01
• First posted: 2024-10-16
• Last updated: 2024-10-16

Locations

1 site across 1 country: South Korea